

# Florian S Eichler

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/878546/publications.pdf>

Version: 2024-02-01

70  
papers

3,714  
citations

147801

31  
h-index

133252

59  
g-index

73  
all docs

73  
docs citations

73  
times ranked

5161  
citing authors

#	ARTICLE	IF	CITATIONS
1	The AAV9 Variant Capsid AAV-F Mediates Widespread Transgene Expression in Nonhuman Primate Spinal Cord After Intrathecal Administration. <i>Human Gene Therapy</i> , 2022, 33, 61-75.	2.7	16
2	Restless Legs Syndrome in X-linked adrenoleukodystrophy. <i>Sleep Medicine</i> , 2022, 91, 31-34.	1.6	5
3	Longitudinal dysphagia assessment in adult patients with nephropathic cystinosis using the Modified Barium Swallow Impairment Profile. <i>Muscle and Nerve</i> , 2022, 66, 223-226.	2.2	2
4	Feasibility of simultaneous high-resolution anatomical and quantitative magnetic resonance imaging of sciatic nerves in patients with Charcot-Marie-Tooth type 1A (CMT1A) at 7T. <i>Muscle and Nerve</i> , 2022, 66, 206-211.	2.2	2
5	Peroxisome Metabolism Contributes to PIEZO2-Mediated Mechanical Allodynia. <i>Cells</i> , 2022, 11, 1842.	4.1	2
6	Practical Approaches and Knowledge Gaps in the Care for Children With Leukodystrophies. <i>Journal of Child Neurology</i> , 2021, 36, 65-78.	1.4	6
7	Unusual Behaviors in a 7-year-old Boy. <i>Pediatrics in Review</i> , 2021, 42, S122-S125.	0.4	0
8	Beyond gait and balance: urinary and bowel dysfunction in X-linked adrenoleukodystrophy. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 14.	2.7	7
9	MRI surveillance of boys with X-linked adrenoleukodystrophy identified by newborn screening: Meta-analysis and consensus guidelines. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 728-739.	3.6	39
10	Neurofilament light chain as a potential biomarker for monitoring neurodegeneration in X-linked adrenoleukodystrophy. <i>Nature Communications</i> , 2021, 12, 1816.	12.8	33
11	Metabolic rerouting via SCD1 induction impacts X-linked adrenoleukodystrophy. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	17
12	The natural history of Canavan disease: 23 new cases and comparison with patients from literature. <i>Orphanet Journal of Rare Diseases</i> , 2021, 16, 227.	2.7	9
13	Gait Difficulties and Postural Instability in Adrenoleukodystrophy. <i>Frontiers in Neurology</i> , 2021, 12, 684102.	2.4	2
14	Neutralizing Antibody Evasion and Transduction with Purified Extracellular Vesicle-Enveloped Adeno-Associated Virus Vectors. <i>Human Gene Therapy</i> , 2021, 32, 1457-1470.	2.7	16
15	A Longitudinal Analysis of Early Lesion Growth in Presymptomatic Patients with Cerebral Adrenoleukodystrophy. <i>American Journal of Neuroradiology</i> , 2021, 42, 1904-1911.	2.4	2
16	Endocrine dysfunction in adrenoleukodystrophy. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 182, 257-267.	1.8	11
17	Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development. <i>Frontiers in Neurology</i> , 2021, 12, 788168.	2.4	24
18	Clinical myopathy in patients with nephropathic cystinosis. <i>Muscle and Nerve</i> , 2020, 61, 74-80.	2.2	15

#	ARTICLE	IF	CITATIONS
19	Clinical trial readiness study of distal myopathy and dysphagia in nephropathic cystinosis. <i>Muscle and Nerve</i> , 2020, 62, 681-687.	2.2	5
20	The Changing Face of Adrenoleukodystrophy. <i>Endocrine Reviews</i> , 2020, 41, 577-593.	20.1	38
21	Clinical and radiographic course of arrested cerebral adrenoleukodystrophy. <i>Neurology</i> , 2020, 94, e2499-e2507.	1.1	21
22	Quantitative oculomotor and nonmotor assessments in late-onset GM2 gangliosidosis. <i>Neurology</i> , 2020, 94, e705-e717.	1.1	17
23	Serine and Lipid Metabolism in Macular Disease and Peripheral Neuropathy. <i>New England Journal of Medicine</i> , 2019, 381, 1422-1433.	27.0	166
24	MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. <i>Neurology</i> , 2019, 92, e1698-e1708.	1.1	41
25	The Landscape of Hematopoietic Stem Cell Transplant and Gene Therapy for X-Linked Adrenoleukodystrophy. <i>Current Treatment Options in Neurology</i> , 2019, 21, 61.	1.8	25
26	Randomized trial of <sc> </sc> -serine in patients with hereditary sensory and autonomic neuropathy type 1. <i>Neurology</i> , 2019, 92, e359-e370.	1.1	83
27	Intrathecal Adeno-Associated Viral Vector-Mediated Gene Delivery for Adrenomyeloneuropathy. <i>Human Gene Therapy</i> , 2019, 30, 544-555.	2.7	21
28	The Natural History of Adrenal Insufficiency in X-Linked Adrenoleukodystrophy: An International Collaboration. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 118-126.	3.6	102
29	Natural history of neurological abnormalities in cerebrotendinous xanthomatosis. <i>Journal of Inherited Metabolic Disease</i> , 2018, 41, 647-656.	3.6	41
30	Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement. <i>Molecular Genetics and Metabolism</i> , 2018, 123, 337-346.	1.1	31
31	Gene Therapy for Cerebral Adrenoleukodystrophy. <i>New England Journal of Medicine</i> , 2018, 378, 490-491.	27.0	2
32	5,10-methenyltetrahydrofolate synthetase deficiency causes a neurometabolic disorder associated with microcephaly, epilepsy, and cerebral hypomyelination. <i>Molecular Genetics and Metabolism</i> , 2018, 125, 118-126.	1.1	18
33	Diagnosis, treatment, and clinical outcomes in 43 cases with cerebrotendinous xanthomatosis. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1169-1178.	1.5	83
34	Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. <i>New England Journal of Medicine</i> , 2017, 377, 1630-1638.	27.0	412
35	Microglial dysfunction as a key pathological change in adrenomyeloneuropathy. <i>Annals of Neurology</i> , 2017, 82, 813-827.	5.3	37
36	Revised consensus statement on the preventive and symptomatic care of patients with leukodystrophies. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 18-32.	1.1	42

#	ARTICLE	IF	CITATIONS
37	Case 38-2017. <i>New England Journal of Medicine</i> , 2017, 377, 2376-2385.	27.0	4
38	ABCD1 dysfunction alters white matter microvascular perfusion. <i>Brain</i> , 2017, 140, 3139-3152.	7.6	24
39	X-linked adrenoleukodystrophy in a chimpanzee due to an ABCD1 mutation reported in multiple unrelated humans. <i>Molecular Genetics and Metabolism</i> , 2017, 122, 130-133.	1.1	5
40	Inherited or acquired metabolic disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 135, 603-636.	1.8	7
41	Neurocognitive clinical outcome assessments for inborn errors of metabolism and other rare conditions. <i>Molecular Genetics and Metabolism</i> , 2016, 118, 65-69.	1.1	28
42	<i>CSF1R</i> mosaicism in a family with hereditary diffuse leukoencephalopathy with spheroids. <i>Brain</i> , 2016, 139, 1666-1672.	7.6	53
43	Metachromatic Leukodystrophy. <i>Journal of Child Neurology</i> , 2016, 31, 1457-1463.	1.4	26
44	Teaching Neuro <i>Images</i> : Vanishing white matter ovarioleukodystrophy. <i>Neurology</i> , 2016, 86, e248.	1.1	0
45	The genetic landscape of X-linked adrenoleukodystrophy: inheritance, mutations, modifier genes, and diagnosis. <i>The Application of Clinical Genetics</i> , 2015, 8, 109.	3.0	96
46	Arginine:glycine amidinotransferase (AGAT) deficiency: Clinical features and long term outcomes in 16 patients diagnosed worldwide. <i>Molecular Genetics and Metabolism</i> , 2015, 116, 252-259.	1.1	55
47	Natural history and biomarkers in hereditary sensory neuropathy type 1. <i>Muscle and Nerve</i> , 2015, 51, 489-495.	2.2	33
48	Disease specific therapies in leukodystrophies and leukoencephalopathies. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 527-536.	1.1	45
49	Case definition and classification of leukodystrophies and leukoencephalopathies. <i>Molecular Genetics and Metabolism</i> , 2015, 114, 494-500.	1.1	185
50	Adenoassociated Virus Serotype 9-Mediated Gene Therapy for X-Linked Adrenoleukodystrophy. <i>Molecular Therapy</i> , 2015, 23, 824-834.	8.2	51
51	Substrate Availability of Mutant SPT Alters Neuronal Branching and Growth Cone Dynamics in Dorsal Root Ganglia. <i>Journal of Neuroscience</i> , 2015, 35, 13713-13719.	3.6	17
52	Brain endothelial dysfunction in cerebral adrenoleukodystrophy. <i>Brain</i> , 2015, 138, 3206-3220.	7.6	61
53	CSF and Blood Levels of GFAP in Alexander Disease. <i>ENeuro</i> , 2015, 2, ENEURO.0080-15.2015.	1.9	30
54	Altered sphingoid base profiles in type 1 compared to type 2 diabetes. <i>Lipids in Health and Disease</i> , 2014, 13, 161.	3.0	37

#	ARTICLE	IF	CITATIONS
55	Hematopoietic Stem Cell Transplantation in the Leukodystrophies: A Systematic Review of the Literature. <i>Neuropediatrics</i> , 2014, 45, 169-174.	0.6	35
56	Hematopoietic Stem Cell Transplantation in the Leukodystrophies: A Systematic Review of the Literature. <i>Neuropediatrics</i> , 2014, 45, e1-e1.	0.6	0
57	Oral l-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. <i>Journal of Clinical Investigation</i> , 2011, 121, 4735-4745.	8.2	172
58	Hereditary Sensory Neuropathy Type 1 Is Caused by the Accumulation of Two Neurotoxic Sphingolipids. <i>Journal of Biological Chemistry</i> , 2010, 285, 11178-11187.	3.4	320
59	Overexpression of the Wild-Type SPT1 Subunit Lowers Desoxysphingolipid Levels and Rescues the Phenotype of HSN1. <i>Journal of Neuroscience</i> , 2009, 29, 14646-14651.	3.6	87
60	Leukodystrophies. <i>Neurologist</i> , 2009, 15, 319-328.	0.7	82
61	Is microglial apoptosis an early pathogenic change in cerebral X-linked adrenoleukodystrophy?. <i>Annals of Neurology</i> , 2008, 63, 729-742.	5.3	140
62	Cerebral White Matter. <i>Annals of the New York Academy of Sciences</i> , 2008, 1142, 266-309.	3.8	410
63	Therapeutics of X-linked adrenoleukodystrophy. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2008, 5, 237-242.	0.5	1
64	Seven-Tesla Proton Magnetic Resonance Spectroscopic Imaging in Adult X-Linked Adrenoleukodystrophy. <i>Archives of Neurology</i> , 2008, 65, 1488.	4.5	34
65	Magnetic Resonance Imaging Detection of Lesion Progression in Adult Patients With X-linked Adrenoleukodystrophy. <i>Archives of Neurology</i> , 2007, 64, 659.	4.5	55
66	Immune Response in Leukodystrophies. <i>Pediatric Neurology</i> , 2007, 37, 235-244.	2.1	38
67	Magnetic Resonance Imaging Evaluation of Possible Neonatal Sinovenous Thrombosis. <i>Pediatric Neurology</i> , 2007, 37, 317-323.	2.1	33
68	Neonatal adrenoleukodystrophy with long-term survival. <i>FASEB Journal</i> , 2007, 21, A401.	0.5	0
69	Proton Magnetic Resonance Spectroscopy and Diffusion-Weighted Imaging in Isolated Sulfite Oxidase Deficiency. <i>Journal of Child Neurology</i> , 2006, 21, 801-805.	1.4	20
70	Proton MR Spectroscopic and Diffusion Tensor Brain MR Imaging in X-linked Adrenoleukodystrophy: Initial Experience. <i>Radiology</i> , 2002, 225, 245-252.	7.3	133